Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by YHB Investment Advisors Inc.

YHB Investment Advisors Inc. grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,583 shares of the medical research company’s stock after buying an additional 133 shares during the period. Thermo Fisher Scientific accounts for about 1.9% of YHB Investment Advisors Inc.’s holdings, making the stock its 10th largest holding. YHB Investment Advisors Inc.’s holdings in Thermo Fisher Scientific were worth $23,180,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in TMO. Cypress Advisory Group LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $253,000. Intact Investment Management Inc. lifted its position in Thermo Fisher Scientific by 34.0% in the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company’s stock valued at $1,353,000 after acquiring an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at $1,121,000. LaFleur & Godfrey LLC increased its position in shares of Thermo Fisher Scientific by 9.1% during the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock worth $15,486,000 after purchasing an additional 2,488 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of Thermo Fisher Scientific by 9.5% in the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company’s stock valued at $687,553,000 after purchasing an additional 114,277 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.33% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on TMO. Argus reduced their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. UBS Group lowered their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Finally, Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

Thermo Fisher Scientific Stock Up 0.6%

Shares of NYSE TMO opened at $400.26 on Tuesday. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average price of $411.66 and a 200 day moving average price of $486.42. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88. The stock has a market capitalization of $151.09 billion, a price-to-earnings ratio of 23.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.11 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.